|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
Kite Pharma
Pharmacyclics
|
|
gptkbp:advertising
|
gptkb:David_A._H._Hsu
|
|
gptkbp:awards
|
Best Places to Work
Top Employer
Innovative_Company
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
Hepatitis research
oncology drugs
Hepatitis B treatment
HIV vaccine research
HIV vaccine
COVID-19 treatments
HIV treatments
Hepatitis C treatments
COVID-19_treatment
COVID-19_research
|
|
gptkbp:collaborations
|
gptkb:FDA
gptkb:CDC
WHO
|
|
gptkbp:drugInterdiction
|
antiviral medications
COVID-19 treatments
oncology treatments
antiretroviral drugs
inflammatory diseases treatments
|
|
gptkbp:employees
|
over 13,000
|
|
gptkbp:focus
|
antiviral drugs
HIV/AIDS treatment
hepatitis C treatment
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:globalPresence
|
over 30 countries
|
|
gptkbp:headCoach
|
gptkb:David_A._H._Hsu
gptkb:James_A._H._Hsu
gptkb:Jessica_A._H._Hsu
gptkb:Michael_A._H._Hsu
gptkb:Robert_A._H._Hsu
gptkb:David_A._L._H._Hsu
gptkb:Michael_J._H._Hsu
gptkb:Sarah_A._H._Hsu
gptkb:Jennifer_A._H._Hsu
gptkb:John_McHutchison
gptkb:Laura_A._H._Hsu
gptkb:Kathy_A._H._Hsu
Megan McGowan
over 13,000 employees
Andrew_Dickinson
|
|
gptkbp:headOfMarketing
|
gptkb:Michele_A._H._Hsu
gptkb:Michael_A._H._Hsu
gptkb:Michele_C._Heller
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market
|
S&P 500
$80 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
|
|
gptkbp:patentCitation
|
Numerous drug patents
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
|
|
gptkbp:products
|
gptkb:Atezolizumab
gptkb:Yescarta
gptkb:Sovaldi
gptkb:Truvada
Antiviral drugs
Biktarvy
Harvoni
HIV medications
Hepatitis C treatments
Veklury
|
|
gptkbp:researchAndDevelopment
|
gptkb:David_A._H._Hsu
$4.1 billion (2020)
|
|
gptkbp:researchFocus
|
HIV/AIDS
Oncology
Hepatitis C
Hepatitis B
Inflammatory diseases
|
|
gptkbp:revenue
|
$24.69 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences_Singapore_Pte._Ltd.
gptkb:Gilead_Sciences_Japan,_Inc.
gptkb:Gilead_Sciences_France_S.A.S.
gptkb:Gilead_Sciences_Ireland_UC
gptkb:Gilead_Sciences_Canada,_Inc.
gptkb:Gilead_Sciences_GmbH
gptkb:Gilead_Sciences_Australia_Pty_Ltd.
gptkb:Gilead_Sciences_Switzerland_AG
gptkb:Gilead_Sciences_Netherlands_B.V.
Gilead_Sciences_(UK)_Ltd.
|
|
gptkbp:sustainabilityInitiatives
|
Diversity and inclusion
Environmental responsibility
Access to medicines
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.gilead.com
|